658 related articles for article (PubMed ID: 33161769)
21. Statin safety: an appraisal from the adverse event reporting system.
Davidson MH; Clark JA; Glass LM; Kanumalla A
Am J Cardiol; 2006 Apr; 97(8A):32C-43C. PubMed ID: 16581327
[TBL] [Abstract][Full Text] [Related]
22. Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System.
Golomb BA; Verden A; Messner AK; Koslik HJ; Hoffman KB
Drug Saf; 2018 Apr; 41(4):403-413. PubMed ID: 29427042
[TBL] [Abstract][Full Text] [Related]
23. Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis.
Chuma M; Nakamoto A; Bando T; Niimura T; Kondo Y; Hamano H; Okada N; Asada M; Zamami Y; Takechi K; Goda M; Miyata K; Yagi K; Yoshioka T; Izawa-Ishizawa Y; Yanagawa H; Tasaki Y; Ishizawa K
Clin Infect Dis; 2022 Oct; 75(8):1416-1422. PubMed ID: 35262686
[TBL] [Abstract][Full Text] [Related]
24. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study.
Dave CV; Winterstein AG; Park H; Cook RL; Hartzema AG
J Affect Disord; 2018 Oct; 238():542-546. PubMed ID: 29936394
[TBL] [Abstract][Full Text] [Related]
25. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins.
Montastruc JL
Br J Clin Pharmacol; 2023 Aug; 89(8):2636-2638. PubMed ID: 37186323
[TBL] [Abstract][Full Text] [Related]
26. The nocebo effect in the context of statin intolerance.
Tobert JA; Newman CB
J Clin Lipidol; 2016; 10(4):739-747. PubMed ID: 27578103
[TBL] [Abstract][Full Text] [Related]
27. Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System.
Jiao XF; Li HL; Jiao XY; Guo YC; Zhang C; Yang CS; Zeng LN; Bo ZY; Chen Z; Song HB; Zhang LL
Sci Rep; 2020 Jul; 10(1):11955. PubMed ID: 32686733
[TBL] [Abstract][Full Text] [Related]
28. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
29. Statins and new-onset diabetes: a retrospective longitudinal cohort study.
Ma T; Tien L; Fang CL; Liou YS; Jong GP
Clin Ther; 2012 Sep; 34(9):1977-83. PubMed ID: 22939164
[TBL] [Abstract][Full Text] [Related]
30. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment.
Howard JP; Wood FA; Finegold JA; Nowbar AN; Thompson DM; Arnold AD; Rajkumar CA; Connolly S; Cegla J; Stride C; Sever P; Norton C; Thom SAM; Shun-Shin MJ; Francis DP
J Am Coll Cardiol; 2021 Sep; 78(12):1210-1222. PubMed ID: 34531021
[TBL] [Abstract][Full Text] [Related]
31. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase.
Essers D; Schäublin M; Kullak-Ublick GA; Weiler S
Eur J Clin Pharmacol; 2019 Mar; 75(3):409-416. PubMed ID: 30430215
[TBL] [Abstract][Full Text] [Related]
32. Modifiable statin characteristics associated with potential statin-related prescribing cascades.
Wang GH; Morris E; Vouri SM; Keshwani S; Schmidt S; Pepine CJ; Smith SM
Pharmacotherapy; 2023 Dec; 43(12):1307-1316. PubMed ID: 37771303
[TBL] [Abstract][Full Text] [Related]
33. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
34. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
36. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).
Penson PE; Bruckert E; Marais D; Reiner Ž; Pirro M; Sahebkar A; Bajraktari G; Mirrakhimov E; Rizzo M; Mikhailidis DP; Sachinidis A; Gaita D; Latkovskis G; Mazidi M; Toth PP; Pella D; Alnouri F; Postadzhiyan A; Yeh HI; Mancini GBJ; von Haehling S; Banach M;
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1596-1622. PubMed ID: 35969116
[TBL] [Abstract][Full Text] [Related]
37. Exploration of adverse events associated with risdiplam use: Retrospective cases from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Yu L; Liu L
PLoS One; 2024; 19(3):e0298609. PubMed ID: 38427665
[TBL] [Abstract][Full Text] [Related]
38. [How to cope with the nocebo effects of statins?].
Lafeber M; Evers AWM; Klok FA
Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36920298
[TBL] [Abstract][Full Text] [Related]
39. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.
Zuccaro P; Mombelli G; Calabresi L; Baldassarre D; Palmi I; Sirtori CR
Pharmacol Res; 2007 Apr; 55(4):310-7. PubMed ID: 17289397
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
